Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652686 · ClinicalTrials.gov registry record · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
A Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), sponsored by Phanes Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 203
- Enrollment target
- 12
- Study locations
NCT05652686: Recruiting Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), sponsored by Phanes Therapeutics.
NCT05652686 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) that is actively recruiting participants, run by Phanes Therapeutics. The registered enrollment target is 203 participants, below the 277-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (27% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05652686, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), is actively recruiting participants, sponsored by Phanes Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 203 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Peluntamig (PT217)
- DRUG Carboplatin + Etoposide
- DRUG Paclitaxel.
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
- Mays Cancer Center / University of Texas, San Antonio - San Antonio
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Maryland
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Missouri
- Washington University School of Medicine (Siteman Cancer Center) - St Louis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Oklahoma
- Sarah Cannon Research Institute University of Oklahoma - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What NCT05652686 shows while recruiting
NCT05652686 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 277-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (27% lower).
The record links to 6 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT05652686 lists 12 locations in 10 states (Massachusetts, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05652686 about?
NCT05652686 is a clinical study titled "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)". This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
What is the current status of trial NCT05652686?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 203 participants. The study started on 2023-09-05. Estimated completion is 2028-08.
What conditions does trial NCT05652686 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC).
What interventions are being tested in trial NCT05652686?
The interventions under investigation include: Atezolizumab (DRUG), Peluntamig (PT217) (DRUG), Carboplatin + Etoposide (DRUG), Paclitaxel. (DRUG).
Who is sponsoring clinical trial NCT05652686?
This trial is sponsored by Phanes Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05652686 being conducted?
This trial has 12 study locations across California, Colorado, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05652686's enrollment target sits among peer trials
203 6th of 12 higher than 7 of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI